Status:
COMPLETED
Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment
Lead Sponsor:
GlaxoSmithKline
Conditions:
Impetigo
Eligibility:
All Genders
9+ years
Phase:
PHASE3
Brief Summary
The goal of this study is to determine if topical SB-275833 ointment, 1% is more effective than a placebo ointment in the treatment of primary impetigo.
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Must have primary impetigo with total lesion area being 100 square centimeters or less.
- Women who could bear children must have a negative urine pregnancy test and agree to either abstain from sexual intercourse or the use of specific effective contraceptive measures.
- Exclusion Criteria:
- Any signs and symptoms of systemic infection.
- Any serious underlying disease that could be imminently life threatening.
Exclusion
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
End Date :
January 1 2006
Estimated Enrollment :
210 Patients enrolled
Trial Details
Trial ID
NCT00133848
Start Date
April 1 2005
End Date
January 1 2006
Last Update
September 23 2016
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Bangalore, India, 560 054
2
GSK Investigational Site
Hyderabad, India, 40000
3
GSK Investigational Site
Rome, Lazio, Italy, 00133
4
GSK Investigational Site
Zapopan, Jalisco, Jalisco, Mexico, 45190